The National Institute for Health and Care Excellence (NICE) has issued technology appraisal guidance for CosentyxTM (secukinumab). Secukinumab is an innovative new treatment licensed for use in adults with moderate-to-severe plaque psoriasis who are candidates for systemic* therapy.1
The announcement by NICE means that its guidance is now final.2 Secukinumab is recommended as an option for adults with severe plaque psoriasis who have failed to respond to, are contraindicated to or cannot take standard systemic therapies.2† The NHS now has a three month deadline to ensure it is made available to these patients.
Approximately two thirds of patients with moderate-to-severe psoriasis are failing to achieve a reduction of 75% in their psoriasis (current treatment goal) with currently available therapies.3
By 22 October 2015, secukinumab, which has consistently demonstrated high levels of skin clearance in clinical trials, should be available to eligible patients within the NHS.4-8